Business Wire

TRIPLE-1-INC.

Share
TRIPLE-1 Inc., Announcement of Two New Products That Use Cutting Edge 7 nm Process and 5 nm Process

TRIPLE-1 Inc. (Headquarters: Hakata-ku, Fukuoka-shi, Fukuoka; Representative Director CEO: Takuya Yamaguchi; Henceforth: TRIPLE-1) has announced two new products: The ASIC "KAMIKAZE Ⅱ" for Bitcoin mining that uses a 7 nm process made by TSMC, and the AI processor "GOKU" for deep learning that uses the world's leading 5 nm process.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200204005385/en/

--- Overview

In the "cryptocurrency mining market" that is driving the miniaturization of semiconductor processes in recent years, an extremely severe business model has been formed that directly links the power performance of semiconductors used for mining with mining proceeds. Starting in February 2017, TRIPLE-1 has been using core know-how involving the designability for cutting edge processes, the optimization of electrical consumption, and the improvement of the yield rate that have been fostered from the development of ASIC (application-specific integrated circuits) for cryptocurrency mining. Development has started on both "KAMIKAZE Ⅱ", the latest high-performance ASIC for Bitcoin mining that uses a 7 nm process made by TSMC, and the AI processor "GOKU" for deep learning that uses the world's leading 5 nm process.

--- Next generation 7 nm Bitcoin mining ASIC "KAMIKAZE Ⅱ" – That design completed

By making use of the know-how fostered from the initial "KAMIKAZE" model, the design for the next generation model "KAMIKAZE Ⅱ" has been finalized. After tape outing to TSMC and the prototype has been inspected, we will start mass production from 2021.

Additionally, we have started to offer reference boards and reference designs for the first "KAMIKAZE" mining machine model, the system that can provide smoother installation support is ready.

< Feature > ASIC Boost is built-in, improving the mining efficiency rapidly

By loading the custom algorithm "ASIC Boost" that improves mining efficiency (it was not loaded on to the first “KAMIKAZE” model), a more highly efficient mining environment is provided. Additionally, by supporting ultra-low voltage drive (supplied voltage 0.2x V), we anticipate a drastic reduction in electrical consumption.

KAMIKAZE / KAMIKAZE Ⅱ Performance specifications comparison

 

KAMIKAZE

KAMIKAZE Ⅱ

Process

TSMC 7 nm

TSMC 7 nm improved process

Die size

3.5 × 3.9 mm

3.0 × 9.0 mm

Package

7 × 7 mm FC-BGA

7 × 12 mm FC-LGA

Input voltage

0.3 V or less

Drives at a lower voltage than KAMIKAZE

Power consumption

1.2 W / chip

6.7 W / chip

Hash rate

23 GHs / chip

240 GHs / chip

Electrical efficiency

52 W / THs

28 W / THs

ASIC Boost

None

Supported

*KAMIKAZE: Chip actual value, KAMIKAZEⅡ: Design target

--- New challenges, enter the AI market

In recent years, various companies have entered the AI chip market, including not only giant IT companies but also fast-growing start-ups in China. As competition for edge AI chip development intensifies, oligopoly supply by several major companies continues in the deep learning AI processor market. Currently there are no mass-produced chips smaller than 12 nm process.

On the other hand, the electrical consumption of data centers is expected to excess 10% of the entire world's electrical energy by 2030. TRIPLE-1 believe that AI processors for deep learning need not only high "computing power" to learn and process a huge amount of data, but also a severe viewpoint on "power consumption" from the viewpoint of energy conservation and cost reduction.

Therefore TRIPLE-1 has launched the project to develop "GOKU", an ultra-low power consumption dedicated deep learning AI processor using the world's most advanced 5nm process, utilizing our unique Low power / High performance technology and design know-how in the most advanced processes.

--- "GOKU", an AI processor for deep learning with the world's leading 5 nm process

The first stage prototype has been completed, and we are inspecting the performance. Realizing the mass production in 2021, we will complete the prototypes closer to mass-produced products within 2020. It will be sold to the equipment and devices manufacturers for data servers or deep learning centers around the world, and we have already begun to discuss with multiple companies.

< Feature > Using the world's leading 5 nm process, it has 10 times higher power efficiency than conventional

Our goal is to reduce power consumption by 1/10 of the equivalent performance compared to conventional products (process: 12 nm), and its feature is low-voltage operation that is inconceivable with existing products.

< Feature > Design to connect multiple calculation units

Like the structure of the human brain, where synapses connect neurons in a complex manner, great amount and very complex inter-core communication is important for deep learning AI processors.

Utilizing the unique circuit design technology of "GOKU", which arranges many small arithmetic units on one large die as much as possible, it is designed to secure the communication (interconnect) band between the arithmetic units as much as possible.

It has been designed to get closer to the human brain.

< Reference > GOKU performance table (Design target)

Process

5 nm

Power consumption

100 W

Peak performance (half-precision)

1 PFLOPS (1,000 TFLOPS)

Electrical efficiency (half-precision)

10 TFLOPS / W

--- TRIPLE-1 outline

Company Name: TRIPLE-1, Inc.
Corporate Headquarter:
7F IT Bldg.Ⅱ,1-14-20 Hakataeki-Higashi, Hakata-ku Fukuoka-shi, Fukuoka, Japan
Representatives: Representative Director CEO Takuya Yamaguchi
The capital: 3662 million 895 thousand and 398 yen (including the capital reserve)

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye